Emergent BioSolutions Inc. provided earnings guidance for the fiscal years 2016 and 2017 and revenue guidance for the first quarter of 2017. On a combined basis, the company anticipates full year 2016 total revenue of $500 to $505 million, the midpoint of which represents a $20 million decline from 2015. This decline is due primarily to lower BioThrax® (Anthrax Vaccine Adsorbed) sales of approximately $237 million versus $294 million, and the impact of seven months of Aptevo-related revenues in 2016 versus a full year in 2015, offset by increases in Other Biodefense product sales and Contract & Grant revenue. On a combined basis, the company anticipates full year 2016 net income of $44 to $48 million, the midpoint of which represents a 27% decline from 2015. Full year 2016 adjusted net income was $64 to $68 million, the midpoint of which represents a 13% decline from 2015. The year-over-year decline reflects the impact of the decline in BioThrax sales. EBITDA expects to be $100 million to $104 million. The company provided earnings guidance for the fiscal year 2017. For the year, the company expects revenue of $500 million to $530 million, net income of $60 million to $70 million, adjusted net income of $70 million to $80 million and EBITDA of $135 million to $145 million. For the first quarter of 2017, the company anticipates total revenues of $120 to $135 million.